AMEX · CCEL

Cryo – Cell International Inc.

$3.46 -$0.04 (-1.14%) 1D Market open

Key Metrics

$28.22M
Market cap
P/E · TTM
Revenue · TTM
−$2.67M
Net income
EPS · TTM $-0.33
Dividend yield 4.3%
Free cash flow $4.94M
Beta · 1Y 0.54
EBITDA · TTM −$1.82M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 26
    From its Apr 27 high, the share price fell 29%.

    Peak close $4.08 on Apr 27; trough close $2.90 on Jun 26. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -29%
  • Jun 26
    The stock moved -24.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 26
  • Apr 28
    The stock moved -15.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 28

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$28.22M
Enterprise value$33.64M
Shares outstanding8.1M
52-wk range$2.72 – $5.43
Avg volume · 20D10.4K
Net cash −$5.42M
Book value / share$-2.24
IndustryServices-Misc Health & Allied Services, Nec
ExchangeAMEX
About Cryo – Cell International Inc.
IPO date
Employees76

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF5.71
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC 16.9% · 20.5%

Financial Health

Current ratio0.62
Quick ratio0.60
Debt / equity-0.45
Debt / EBITDA -4.57
Net cash −$5.42M
Working capital−$6.69M

Cash Flow · TTM

Operating CF $5.18M
Capex −$235.49K
Free cash flow $4.94M
Buybacks
Dividends paid $1.21M
Shareholder yield 4.3%

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-02-28 · computed by TickerWolf from SEC filings